Search

Your search keyword '"Naim Farhat"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Naim Farhat" Remove constraint Author: "Naim Farhat"
37 results on '"Naim Farhat"'

Search Results

1. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

4. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

5. Relationship between left main coronary artery plaque burden and nonleft main coronary atherosclerosis

6. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

7. Predictors of Plaque Rupture Within Nonculprit Fibroatheromas in Patients With Acute Coronary Syndromes

8. Internet Presentation of Departments of Pediatric Surgery in Germany and Their Compliance with Recommended Criteria for Promoting Services and Offering Professional Information for Patients

9. Usefulness of Coronary Atheroma Burden to Predict Cardiovascular Events in Patients Presenting With Acute Coronary Syndromes (from the PROSPECT Study)

10. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies

11. Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes

12. Non-Fibroatheroma Lesion Phenotype and Long-Term Clinical Outcomes

13. Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study

14. An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries

15. Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)

16. Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting Stents

17. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial

18. A Novel Filter-Based Distal Embolic Protection Device for Percutaneous Intervention of Saphenous Vein Graft Lesions

19. PREDICTORS OF PLAQUE RUPTURE WITHIN FIBROATHEROMAS IN PATIENTS WITH ACUTE CORONARY SYNDROMES: THE PROSPECT STUDY

20. THE IMPACT OF NON–FIBROATHEROMA LESION PHENOTYPE ON LONG–TERM CLINICAL OUTCOMES: A SUBSTUDY ANALYSIS FROM PROSPECT

21. Relation between angiographic lesion severity, vulnerable plaque morphology and future adverse cardiac events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study)

22. CHARACTERISTICS AND CLINICAL SIGNIFICANCE OF ANGIOGRAPHICALLY MILD LESIONS IN ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE PROSPECT STUDY

23. Gender and the Extent of Coronary Atherosclerosis, Plaque Composition, and Clinical Outcomes in Acute Coronary Syndromes

24. A prospective natural-history study of coronary atherosclerosis

25. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)

26. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)

27. EVEN AFTER PERCUTANEOUS CORONARY INTERVENTION OF ANGIOGRAPHICALLY SIGNIFICANT LESIONS, IVUS-DEFINED HIGH-GRADE STENOSES ARE COMMON. A BASELINE IVUS ANALYSIS FROM THE PROSPECT TRIAL

28. INCOMPLETE THREE-VESSEL INTRAVASCULAR IMAGING IN THE PROSPECT TRIAL: IMPLICATIONS FOR PRE-EMPTIVE VULNERABLE PLAQUE DETECTION

29. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial

30. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial

31. Clinical evaluation of the Zilver vascular stent for symptomatic iliac artery disease

32. THE REMODELING PARADOX AND CLINICAL OUTCOMES: INSIGHTS FROM PROSPECT

33. Performance of everolimus-eluting and paclitaxel-eluting coronary stents in women: 2-year outcomes from the SPIRIT IV trial

34. THE 2.25 MILLIMETER XIENCE V® EVEROLIMUS ELUTING CORONARY STENT SYSTEM FOR THE TREATMENT OF SMALL CORONARY ARTERIES: THE SPIRIT SMALL VESSEL TRIAL

35. Characteristics and Clinical Significance of Angiographically Mild Lesions in Acute Coronary Syndromes

36. TCT-367 Evolution of Plaque Volume and Lesion Morphology in Patients with Non-culprit Lesion-related Events: A serial VH-IVUS analysis from the PROSPECT study

37. TCT-658 Relationship between the severity of left main coronary artery (LMCA) disease and overall coronary atherosclerotic burden: The PROSPECT study

Catalog

Books, media, physical & digital resources